Tatva Chintan Pharma Chem Limited (IN:TATVA)
:TATVA
Want to see IN:TATVA full AI Analyst Report?
Top Page
Tatva Chintan Pharma Chem Limited
(TATVA)
Select Model
Select Model
Rating:53Neutral
Price Target:
₹1,346.00
▼(-3.05% Downside)
Action:ReiteratedDate:01/24/26
The score is held back primarily by weak technical momentum (price below key moving averages with negative MACD) and expensive valuation (very high P/E with minimal dividend yield). Financial performance is mixed: balance sheet strength helps, but profitability volatility and negative free cash flow materially reduce overall quality.
Positive Factors
Strong balance sheet
Conservative leverage and a robust equity base give the company financial resilience across cycles, supporting supplier and customer confidence, allowing access to capital for strategic investments, and reducing bankruptcy risk. This underpins durable operational continuity and strategic optionality.
Negative Factors
Negative free cash flow from capex
Sustained negative free cash flow driven by heavy capex pressures liquidity and forces reliance on external financing or equity to fund growth. If capex returns lag expectations, this can constrain dividends, increase financing costs, and impair capital allocation flexibility over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
Conservative leverage and a robust equity base give the company financial resilience across cycles, supporting supplier and customer confidence, allowing access to capital for strategic investments, and reducing bankruptcy risk. This underpins durable operational continuity and strategic optionality.
Read all positive factors
Tatva Chintan Pharma Chem Limited (TATVA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹29.73B
Dividend Yield0.07%
Average Volume (3M)12.52K
Price to Earnings (P/E)51.4
Beta (1Y)1.07
Revenue Growth28.53%
EPS Growth129.16%
CountryIN
Employees689
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)6.80
Shares Outstanding23,392,056
10 Day Avg. Volume25,333
30 Day Avg. Volume12,516
Financial Highlights & Ratios
PEG Ratio-3.55
Price to Book (P/B)2.24
Price to Sales (P/S)4.33
P/FCF Ratio-32.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27
Revenue Forecast (FY)₹6.21B
Tatva Chintan Pharma Chem Limited Business Overview & Revenue Model
Company Description
Tatva Chintan Pharma Chem Limited manufactures and sells specialty chemicals in India. The company offers a portfolio of structure directing agents for zeolites synthesis; phase transfer catalysts; electrolyte salts for super capacitor batteries; ...
How the Company Makes Money
Tatva Chintan primarily makes money by manufacturing and selling specialty chemicals to business customers (B2B), generating revenue from product sales across its main categories: (1) Structure-Directing Agents (SDAs): sold to manufacturers of zeo...
Tatva Chintan Pharma Chem Limited Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
72
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.34B | 3.83B | 3.94B | 4.24B | 4.34B | 3.00B |
| Gross Profit | 2.22B | 1.84B | 2.11B | 1.91B | 2.32B | 1.43B |
| EBITDA | 567.40M | 342.13M | 689.34M | 676.30M | 1.08B | 666.37M |
| Net Income | 177.36M | 57.13M | 303.54M | 454.87M | 958.74M | 522.62M |
Balance Sheet | ||||||
| Total Assets | 9.08B | 8.36B | 8.19B | 7.56B | 6.58B | 3.15B |
| Cash, Cash Equivalents and Short-Term Investments | 178.47M | 117.01M | 456.68M | 412.15M | 638.19M | 53.24M |
| Total Debt | 830.13M | 363.88M | 142.71M | 1.70B | 1.20B | 902.48M |
| Total Liabilities | 1.53B | 974.25M | 816.36M | 2.42B | 1.85B | 1.49B |
| Stockholders Equity | 7.54B | 7.39B | 7.37B | 5.15B | 4.73B | 1.66B |
Cash Flow | ||||||
| Free Cash Flow | -426.18M | -516.01M | -304.71M | -1.75B | -687.79M | 33.49M |
| Operating Cash Flow | 133.81M | 246.71M | 980.44M | 277.83M | 203.78M | 243.19M |
| Investing Cash Flow | -577.76M | -652.54M | -1.21B | -1.01B | -1.97B | -207.02M |
| Financing Cash Flow | 457.32M | 165.66M | 305.19M | 377.95M | 2.35B | -44.80M |
Tatva Chintan Pharma Chem Limited Technical Analysis
Positive
1388.35
Price Trends
1176.04
Positive
1270.94
Positive
1199.62
Positive
Market Momentum
22.17
Negative
63.18
Neutral
89.05
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TATVA, the sentiment is Positive. The current price of 1388.35 is above the 20-day moving average (MA) of 1166.28, above the 50-day MA of 1176.04, and above the 200-day MA of 1199.62, indicating a bullish trend. The MACD of 22.17 indicates Negative momentum. The RSI at 63.18 is Neutral, neither overbought nor oversold. The STOCH value of 89.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:TATVA.
Tatva Chintan Pharma Chem Limited Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹26.69B | 23.71 | ― | 0.65% | 2.07% | -16.12% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | ₹26.12B | 29.38 | ― | 0.97% | 8.37% | 19.15% | |
57 Neutral | ₹23.79B | 0.22 | ― | ― | -19.38% | 1266.07% | |
56 Neutral | ₹12.63B | 26.88 | ― | 0.24% | 14.39% | 75.07% | |
53 Neutral | ₹29.73B | 51.39 | ― | 0.07% | 28.53% | 129.16% | |
52 Neutral | ₹17.74B | 95.28 | ― | 0.03% | 16.55% | -10.39% |
* Basic Materials Sector Average
IN:TATVA
Tatva Chintan Pharma Chem Limited
1,325.95
602.82
83.36%
IN:FCL
Fineotex Chemical Limited
23.09
-0.97
-4.03%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
92.45
26.64
40.48%
IN:KIRIINDUS
Kiri Industries Limited
414.15
-166.05
-28.62%
IN:PUNJABCHEM
Punjab Chemicals & Crop Protection Ltd.
1,065.70
-9.55
-0.89%
IN:YASHO
Yasho Industries Ltd.
1,483.10
-172.59
-10.42%
Tatva Chintan Pharma Chem Limited Corporate Events
Tatva Chintan Plans Virtual Investor Meeting With OysterRock Capital
Mar 19, 2026
Tatva Chintan Pharma Chem Limited has scheduled a virtual one-on-one investor meeting with OysterRock Capital on 24 March 2026, as disclosed under SEBI’s listing obligations framework. The company emphasized that only publicly available info...
Tatva Chintan Faces New Gas Supply Curbs and Pricing Regime Under Government Order
Mar 14, 2026
Tatva Chintan Pharma Chem has disclosed that its natural gas supply will be regulated under the Government of India’s new Natural Gas (Supply Regulation) Order, 2026, issued in response to Middle East geopolitical disruptions. Industrial gas...
Tatva Chintan Schedules Compliant Virtual Investor Meet on 16 March 2026
Mar 11, 2026
Tatva Chintan Pharma Chem Limited has scheduled a virtual one-on-one investor meeting with Ask Wealth Advisor Private Limited on 16 March 2026, in line with market disclosure norms under SEBI’s Listing Obligations and Disclosure Requirements...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.